TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20550748

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk product
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional yoghurt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactobacillus delbrueckii
Number of subjects: 0
Study: 18176337

Group type: EXPERIMENTAL
Intervention: Dexmethylphenidate extended-release (D-MPH-ER) 20 mg/day
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 15792207

Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty (Group A)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Dynamic screw fixation (Group B)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study: 12028210

Group type: EXPERIMENTAL
Intervention: Morning bright light
Number of subjects: 77

Group type: COMPARATOR
Intervention: Evening bright light
Number of subjects: 77

Group type: COMPARATOR
Intervention: Daytime sleep restriction
Number of subjects: 77

Group type: COMPARATOR
Intervention: Evening dim red light
Number of subjects: 77
Study: 10339734

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms twice daily
Number of subjects: 20
Study: 7564470

Group type: EXPERIMENTAL
Intervention: Busulfan plus continuous oral vitamin A
Number of subjects: 153

Group type: COMPARATOR
Intervention: Busulfan
Number of subjects: 153
Study: 1948817

Group type: EXPERIMENTAL
Intervention: Protamine chloride 80 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Protamine chloride 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Protamine chloride 20-100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Protamine chloride 60-100 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 6119712

Group type: EXPERIMENTAL
Intervention: Neuroleptic therapy with constant doses of butyrophenones
Number of subjects: 33
Study: 30885522

Group type: EXPERIMENTAL
Intervention: Low frequency pulsed electromagnetic field (PEMF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-PEMF (NPEMF)
Number of subjects: 0
Study: 29714073

Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial component
Number of subjects: 59

Group type: COMPARATOR
Intervention: Metal-backed tibial component
Number of subjects: 59
Study: 27636018

Group type: EXPERIMENTAL
Intervention: Kisspeptin-10 (4 μg/kg/h) infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: NK3R antagonist AZD4901 40 mg twice daily orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: NK3R antagonist AZD4901
Number of subjects: 10
Study: 24831288

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (zhiji management) for 3 months
Number of subjects: 273

Group type: COMPARATOR
Intervention: Late group (control phase)
Number of subjects: 273
Study: 22307881

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Veterans Health Administration Vocational Rehabilitation Program (VRP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: IPS
Number of subjects: 85

Group type: COMPARATOR
Intervention: VRP
Number of subjects: 85
Study: 20621262

Group type: EXPERIMENTAL
Intervention: Computerized tailored physical activity reports
Number of subjects: 394

Group type: COMPARATOR
Intervention: General reports on preventive screening
Number of subjects: 394
Study: 17940786

Group type: EXPERIMENTAL
Intervention: Submucosal infiltration with 2 mg/kg tramadol in 3 ml of normal saline (1.5 ml per tonsil)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline only (placebo)
Number of subjects: 40
Study: 15965309

Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg administered 4 times during the day with controlled-release levodopa/carbidopa 100 mg/25 mg (Sinemet CR)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Entacapone 200 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 12798612

Group type: EXPERIMENTAL
Intervention: MDCK cell grown influenza vaccine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Egg-derived influenza vaccine
Number of subjects: 48
Study: 10822319

Group type: EXPERIMENTAL
Intervention: Perindopril 4-8 mg/daily
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 8861091

Group type: EXPERIMENTAL
Intervention: EEG mapping in depressed patients (Group C)
Number of subjects: 129

Group type: COMPARATOR
Intervention: EEG mapping in menopausal syndrome patients without depression (Group A and B)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Correlation of estradiol levels with EEG measures
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Correlation of EEG measures with Hamilton depression score (HAMD)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Frontal asymmetry index in depressed patients (Group C)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Frontal asymmetry index in normal controls
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Correlation of frontal asymmetry index with Hamilton depression score
Number of subjects: 129
Study: 1513922

Group type: EXPERIMENTAL
Intervention: Haloperidol (0.5 to 3.5 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6381081

Group type: EXPERIMENTAL
Intervention: Treatment B (postural drainage and periodic application of a face mask with positive expiratory pressure)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Treatment C (PEP in the sitting position)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treatment A (postural drainage, percussion and vibration)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Treatment D (forced expiration technique in the sitting position)
Number of subjects: 14
Study: 30586729

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training (10 months of training followed by 14 months of maintenance exercise)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High-intensity exercise training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Stretching/balance control
Number of subjects: 61
Study: 27288691

Group type: EXPERIMENTAL
Intervention: Encuentro program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 27049053

Group type: EXPERIMENTAL
Intervention: Trial preparation (2 × 250 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference preparation (2 × 250 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Trial preparation and Reference preparation
Number of subjects: 20
Study: 24692001

Group type: EXPERIMENTAL
Intervention: Prestroke statin use (n=51)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prestroke nonstatin use (n=30)
Number of subjects: 100
Study: 23091148

Group type: EXPERIMENTAL
Intervention: AL (25 mg of allopurinol/kg of body mass)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AR (AL for 2 wk followed by allopurinol withdrawal over wk 3)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: UAF (AL plus 6.25 g of UA sodium salt/kg of feed)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: UAI (AL plus 120 mg of UA sodium salt injected daily)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: INO (0.6 M inosine/kg of feed)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: INOAL (INO plus 50 mg of allopurinol/kg of body mass)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (0)
Number of subjects: 25
Study: 19605567

Group type: EXPERIMENTAL
Intervention: Consumption of sucrose (37.5 g) 2 h after breakfast and lunch
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (water without sucrose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Consumption of sucrose (75 g, equivalent to 2 cans of a soft drink)
Number of subjects: 31
Study: 17478225

Group type: EXPERIMENTAL
Intervention: Acute tonsillitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recurrent tonsillitis
Number of subjects: 0
Study: 15564986

Group type: EXPERIMENTAL
Intervention: Home blood pressure measurement
Number of subjects: 400

Group type: COMPARATOR
Intervention: Office blood pressure measurement
Number of subjects: 400
Study: 10881251

Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 978

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 978

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 978
Study: 8931684

Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate 1.8 mg/kg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Dolasetron mesylate 0.6 mg/kg
Number of subjects: 62
Study: 1563056

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (2 ml, 8 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hyperbaric tetracaine (2 ml, 8 mg)
Number of subjects: 30
Study: 3910157

Group type: EXPERIMENTAL
Intervention: High-dose fractionated pre-operative irradiation (25.5 Gy in 5-7 days)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Postoperative irradiation (60 Gy in 8 weeks)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 360
Study: 30833449

Group type: EXPERIMENTAL
Intervention: High flavonoid cocoa beverage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low flavonoid cocoa beverage (control)
Number of subjects: 40
Study: 28770642

Group type: EXPERIMENTAL
Intervention: Negative emotional state
Number of subjects: 70

Group type: COMPARATOR
Intervention: Neutral emotional state
Number of subjects: 70
Study: 26583953

Group type: EXPERIMENTAL
Intervention: Slackline training, 6 weeks, 2 times per week
Number of subjects: 24
Study: 22664565

Group type: EXPERIMENTAL
Intervention: Ena-Bond-Enamel HFO (n=48)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond-Miris2 (n=48)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intact teeth
Number of subjects: 23

Group type: COMPARATOR
Intervention: Small restorations
Number of subjects: 23

Group type: COMPARATOR
Intervention: Big restorations
Number of subjects: 23
Study: 20736816

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A injections
Number of subjects: 36
Study: 19133087

Group type: EXPERIMENTAL
Intervention: ProRoot Endo Sealer
Number of subjects: 3

Group type: COMPARATOR
Intervention: ZOE‐based sealer
Number of subjects: 3

Group type: COMPARATOR
Intervention: Epoxy resin‐based sealer
Number of subjects: 3
Study: 15669614

Group type: EXPERIMENTAL
Intervention: Stimuli equated at the cornea
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stimuli corrected for ocular media density differences (equated at the retina)
Number of subjects: 20
Study: 12657984

Group type: EXPERIMENTAL
Intervention: Uncertainty Management Intervention provided to the patient only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncertainty Management Intervention supplemented by delivery to the patient and family member
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncertainty Management Intervention
Number of subjects: 0
Study: 10847307

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 2967

Group type: COMPARATOR
Intervention: Other antipsychotic drugs (Control)
Number of subjects: 2967
Study: 8838441

Group type: EXPERIMENTAL
Intervention: 311C90 (1-50 mg, single oral doses)
Number of subjects: 12
Study: 1289588

Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) at a mean dose of 8.4 mg/kg, administered 3-4 times daily for an average of 6 days.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) at a daily dose of 30.1-45.0 mg/kg.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) against 53 isolates of Staphylococcus aureus.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Cefprozil (CFPZ) against Methicillin-resistant S. aureus (MRSA).
Number of subjects: 73

Group type: COMPARATOR
Intervention: Cefprozil (CFPZ) compared to other antibiotics (CEX, CCL, ABPC, DMPPC, MCIPC).
Number of subjects: 73
Study: 3885985

Group type: EXPERIMENTAL
Intervention: Bepridil (400 mg/day for 10 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30353579

Group type: EXPERIMENTAL
Intervention: 0.1% DBP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.2% DBP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.3% DBP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.4% DBP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 0.5% DBP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: DBP (various levels)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (0% DBP)
Number of subjects: 120
Study: 30173287

Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry juice (MTCJ) supplementation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study: 26700585

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TZDs
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GLP-1 analogues
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25055812

Group type: EXPERIMENTAL
Intervention: Clinical Trial Agreement introduced
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Characteristics of site investigators and research culture
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Delay in approval of the new Clinical Trial Agreement
Number of subjects: 39
Study: 20121112

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m² and cetuximab 400 mg/m² loading dose followed by 250 mg/m² for 6 weeks with pelvic RT (DL 1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m² and cetuximab 400 mg/m² loading dose followed by 250 mg/m² for 6 weeks with pelvic RT (DL 2)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m² and cetuximab with extended field radiation therapy (EFRT) (DL 1)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cisplatin and cetuximab with EFRT (feasibility phase)
Number of subjects: 54
Study: 20473913

Group type: EXPERIMENTAL
Intervention: Catumaxomab (10, 20, 50 and 150 mug i.p. infusion on Days 0, 3, 7 and 10)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Catumaxomab
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control (paracentesis alone)
Number of subjects: 258
Study: 18556337

Group type: EXPERIMENTAL
Intervention: Insulin administration
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: DQB*0302 allele presence
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: DQB*0301 allele presence
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: INS-23 genotype
Number of subjects: 708
Study: 19687359

Group type: EXPERIMENTAL
Intervention: Propranolol 20 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 14759614

Group type: EXPERIMENTAL
Intervention: EE20/LNG100
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EE30/LNG150
Number of subjects: 12
Study: 11334895

Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 16

Group type: COMPARATOR
Intervention: desogestrel/EE COC
Number of subjects: 16
Study: 9220209

Group type: EXPERIMENTAL
Intervention: Valsartan 20 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Valsartan 320 mg
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 8501477

Group type: EXPERIMENTAL
Intervention: Clinical experiment abstract
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case-control study abstract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo abstract
Number of subjects: 0
Study: 3792435

Group type: EXPERIMENTAL
Intervention: Aspirin 5 mg/kg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg/kg
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Aspirin 15 mg/kg
Number of subjects: 145
Study: 12365879

Group type: EXPERIMENTAL
Intervention: Needs-based intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Specific preventive intervention (low-dose risperidone therapy, mean dosage 1.3 mg/d, and cognitive behavior therapy)
Number of subjects: 59
Study: 31567716

Group type: COMPARATOR
Intervention: Bracing (orthosis)
Number of subjects: 119

Group type: COMPARATOR
Intervention: No bracing (no orthosis)
Number of subjects: 119
Study: 29938452

Group type: EXPERIMENTAL
Intervention: UI05MSP015CT (15 mg once a day)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Mosapride (5 mg three times a day, control group)
Number of subjects: 138
Study: 26360545

Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Behavioral Therapy (CCBT)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 199
Study: 24577019

Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine (0.2 μg/kg/h titrated to 0.7 μg/kg/h)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: IV dexmedetomidine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Use of midazolam
Number of subjects: 33

Group type: COMPARATOR
Intervention: Episodes of severe bradycardia (heart rate ≤ 50 beats/min)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Episodes of hypotension (systolic BP ≤ 90 mm Hg)
Number of subjects: 33
Study: 21796409

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combined Training (SET)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 108
Study: 20939245

Group type: EXPERIMENTAL
Intervention: Biofeedback with bone turnover markers
Number of subjects: 781

Group type: COMPARATOR
Intervention: No biofeedback
Number of subjects: 781
Study: 18845330

Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 16553198

Group type: EXPERIMENTAL
Intervention: Needle catheter jejunostomy (NCJ)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard 'Witzel' tube jejunostomy (STJ)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Early postoperative enteral nutrition (EPEN) via jejunostomy
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Jejunostomy and EPEN on first operation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Jejunostomy done at reoperation
Number of subjects: 37
Study: 11954942

Group type: EXPERIMENTAL
Intervention: Quinapril treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 10362386

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (40 mg, two patches) administered 12 hours before exercise
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo patches administered 12 hours before exercise
Number of subjects: 25
Study: 7677554

Group type: EXPERIMENTAL
Intervention: Communication-skills training (two courses: problem-defining skills and emotion-handling skills)
Number of subjects: 648

Group type: EXPERIMENTAL
Intervention: Communication-skills training
Number of subjects: 648

Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 648
Study: 2209320

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 6108588

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29876831

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Social activity intervention
Number of subjects: 91
Study: 29205807

Group type: EXPERIMENTAL
Intervention: Telephone follow-up
Number of subjects: 179

Group type: COMPARATOR
Intervention: Clinic review
Number of subjects: 179
Study: 28531791

Group type: EXPERIMENTAL
Intervention: Brioche group (65 g brioche enriched in protein and energy, 12.8 g protein, 180 kcal)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Brioche group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Supplement group (200-ml energy-dense liquid, 14 g protein, 200 kcal)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (usual breakfast only)
Number of subjects: 68
Study: 24668358

Group type: EXPERIMENTAL
Intervention: Core stability program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Task-oriented motor training program
Number of subjects: 22
Study: 22464973

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 10 mg bid
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 20 mg bid
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 30 mg bid
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Olanzapine 15 mg once-daily
Number of subjects: 498

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: All JNJ-37822681 groups
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: JNJ-37822681
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 10 mg bid vs Olanzapine
Number of subjects: 498
Study: 20080287

Group type: COMPARATOR
Intervention: Sildenafil 100 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Tadalafil 20 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 17628221

Group type: EXPERIMENTAL
Intervention: Ibuprofen and caffeine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ibuprofen and placebo
Number of subjects: 12
Study: 15902278

Group type: EXPERIMENTAL
Intervention: Ropivacaine hydrochloride 0.75% (6 patients)
Number of subjects: 11

Group type: COMPARATOR
Intervention: NaCl 0.9% (5 patients)
Number of subjects: 11
Study: 12809197

Group type: EXPERIMENTAL
Intervention: Rivermead Mobility Index at T0
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Rivermead Mobility Index at T2
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Timed walking test at T2
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Effect size
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Scalability coefficients
Number of subjects: 140